These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma. Wong MH; Xue A; Julovi SM; Pavlakis N; Samra JS; Hugh TJ; Gill AJ; Peters L; Baxter RC; Smith RC Clin Cancer Res; 2014 Aug; 20(15):4047-58. PubMed ID: 24895459 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of Survival Pathways MAPK and NF-kB Triggers Apoptosis in Pancreatic Ductal Adenocarcinoma Cells via Suppression of Autophagy. Papademetrio DL; Lompardía SL; Simunovich T; Costantino S; Mihalez CY; Cavaliere V; Álvarez É Target Oncol; 2016 Apr; 11(2):183-95. PubMed ID: 26373299 [TBL] [Abstract][Full Text] [Related]
4. Wu Y; Zhang F; Xu P; Li P Curr Cancer Drug Targets; 2024; 24(7):749-759. PubMed ID: 38310464 [TBL] [Abstract][Full Text] [Related]
5. The therapeutic targeting of the FGFR1/Src/NF-κB signaling axis inhibits pancreatic ductal adenocarcinoma stemness and oncogenicity. Lai SW; Bamodu OA; Tsai WC; Chang YM; Lee WH; Yeh CT; Chao TY Clin Exp Metastasis; 2018 Oct; 35(7):663-677. PubMed ID: 29987671 [TBL] [Abstract][Full Text] [Related]
6. The inhibition of cell proliferation and induction of apoptosis in pancreatic ductal adenocarcinoma cells by verrucarin A, a macrocyclic trichothecene, is associated with the inhibition of Akt/NF-кB/mTOR prosurvival signaling. Deeb D; Gao X; Liu Y; Zhang Y; Shaw J; Valeriote FA; Gautam SC Int J Oncol; 2016 Sep; 49(3):1139-47. PubMed ID: 27573873 [TBL] [Abstract][Full Text] [Related]
7. Impact of death receptor signaling on the malignancy of pancreatic ductal adenocarcinoma. Röder C; Trauzold A; Kalthoff H Eur J Cell Biol; 2011; 90(6-7):450-5. PubMed ID: 21129814 [TBL] [Abstract][Full Text] [Related]
8. Therapeutic targeting of apoptotic pathways: novel aspects in pancreatic cancer. Neesse A; Gress TM; Michl P Curr Pharm Biotechnol; 2012 Sep; 13(11):2273-82. PubMed ID: 21605073 [TBL] [Abstract][Full Text] [Related]
9. Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer. Totiger TM; Srinivasan S; Jala VR; Lamichhane P; Dosch AR; Gaidarski AA; Joshi C; Rangappa S; Castellanos J; Vemula PK; Chen X; Kwon D; Kashikar N; VanSaun M; Merchant NB; Nagathihalli NS Mol Cancer Ther; 2019 Feb; 18(2):301-311. PubMed ID: 30404927 [TBL] [Abstract][Full Text] [Related]
10. Increased Serotonin Signaling Contributes to the Warburg Effect in Pancreatic Tumor Cells Under Metabolic Stress and Promotes Growth of Pancreatic Tumors in Mice. Jiang SH; Li J; Dong FY; Yang JY; Liu DJ; Yang XM; Wang YH; Yang MW; Fu XL; Zhang XX; Li Q; Pang XF; Huo YM; Li J; Zhang JF; Lee HY; Lee SJ; Qin WX; Gu JR; Sun YW; Zhang ZG Gastroenterology; 2017 Jul; 153(1):277-291.e19. PubMed ID: 28315323 [TBL] [Abstract][Full Text] [Related]
11. Phosphoglycerate Mutase 1 (PGAM1) Promotes Pancreatic Ductal Adenocarcinoma (PDAC) Metastasis by Acting as a Novel Downstream Target of the PI3K/Akt/mTOR Pathway. Liu X; Tan X; Liu P; Wu Y; Qian S; Zhang X Oncol Res; 2018 Aug; 26(7):1123-1131. PubMed ID: 29386088 [TBL] [Abstract][Full Text] [Related]
12. Preclinical pharmacodynamic evaluation of a new Src/FOSL1 inhibitor, LY-1816, in pancreatic ductal adenocarcinoma. Yang W; Meng L; Chen K; Tian C; Peng B; Zhong L; Zhang C; Yang X; Zou J; Yang S; Li L Cancer Sci; 2019 Apr; 110(4):1408-1419. PubMed ID: 30618127 [TBL] [Abstract][Full Text] [Related]
13. Phosphoinositide-3-kinase signaling controls S-phase kinase-associated protein 2 transcription via E2F1 in pancreatic ductal adenocarcinoma cells. Reichert M; Saur D; Hamacher R; Schmid RM; Schneider G Cancer Res; 2007 May; 67(9):4149-56. PubMed ID: 17483325 [TBL] [Abstract][Full Text] [Related]
14. Combined inhibition of the PI3K/mTOR/MEK pathway induces Bim/Mcl-1-regulated apoptosis in pancreatic cancer cells. Burmi RS; Maginn EN; Gabra H; Stronach EA; Wasan HS Cancer Biol Ther; 2019; 20(1):21-30. PubMed ID: 30261145 [TBL] [Abstract][Full Text] [Related]
15. Cell death in pancreatic cancer: from pathogenesis to therapy. Chen X; Zeh HJ; Kang R; Kroemer G; Tang D Nat Rev Gastroenterol Hepatol; 2021 Nov; 18(11):804-823. PubMed ID: 34331036 [TBL] [Abstract][Full Text] [Related]
16. Longikaurin E induces apoptosis of pancreatic cancer cells via modulation of the p38 and PI3K/AKT pathways by ROS. Cheng HB; Bo Y; Shen WX; Ren XG; Tan JN; Jia ZR; Xu CL Naunyn Schmiedebergs Arch Pharmacol; 2015 Jun; 388(6):623-34. PubMed ID: 25743573 [TBL] [Abstract][Full Text] [Related]
17. Induction of cell death in pancreatic ductal adenocarcinoma by indirubin 3'-oxime and 5-methoxyindirubin 3'-oxime in vitro and in vivo. Sano M; Ichimaru Y; Kurita M; Hayashi E; Homma T; Saito H; Masuda S; Nemoto N; Hemmi A; Suzuki T; Miyairi S; Hao H Cancer Lett; 2017 Jul; 397():72-82. PubMed ID: 28347789 [TBL] [Abstract][Full Text] [Related]
18. Overexpression of HMGA1 promotes anoikis resistance and constitutive Akt activation in pancreatic adenocarcinoma cells. Liau SS; Jazag A; Ito K; Whang EE Br J Cancer; 2007 Mar; 96(6):993-1000. PubMed ID: 17342093 [TBL] [Abstract][Full Text] [Related]
19. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells. Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203 [TBL] [Abstract][Full Text] [Related]
20. New Pancreatic Cancer Biomarkers eIF1, eIF2D, eIF3C and eIF6 Play a Major Role in Translational Control in Ductal Adenocarcinoma. Golob-Schwarzl N; Puchas P; Gogg-Kamerer M; Weichert W; Göppert B; Haybaeck J Anticancer Res; 2020 Jun; 40(6):3109-3118. PubMed ID: 32487605 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]